Skip to main content

Bioterrorismus — eine reale Bedrohung?

  • Chapter
Infektiologie Aktuelle Aspekte

Part of the book series: Infektiologie Aktuelle Aspekte ((INFEKTIOLOGIE))

  • 43 Accesses

Zusammenfassung

Terror durch politische, religiöse und andere Gruppierungen ist weltweit nahezu all-täglich geworden. Bisher war der Einsatz von biologischen Kampfstoffen die Ausnahme, doch schon alleine der Kostenfaktor könnte B-Waffen für Terroristen und manche Staaten attraktiv machen. Eine Studie der Vereinten Nationen 1969 ergab, daß die Kosten eines vernichtenden Angriffs auf eine Stadt pro Quadratkilometer mit konventionellen Waffen etwa 2000 $, mit nuklearen Waffen 800 $, mit Nervengas 600 $, mit biologischen Waffen jedoch nur 1 $ betragen würden1. Keime und Toxine können als Staub, Aerosol, direkte Kontaminierung oder über Vektoren unbemerkt ausgebracht werden. Impfungen und medikamentöse Prophylaxen ermöglichen Attentätern das Arbeiten mit einigen B-Kampfstoffen auch ohne eigene Gefährdung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. North Atlantic Treaty Organization. NATO Handbook on the Medical Aspects of NBC Defensive Operations. A-Med-P6, part 2, Biological. June 1992. Final draft.

    Google Scholar 

  2. Harbich H, Schlägel R, Medizinische Versorgung von Opfern biologischer Kriegsführung. SDB 146a, Mai 2000, BMLV Erlaß GZ: 55.210/250-4.4/99

    Google Scholar 

  3. Alibek K, Handelman S, Biohazard, Random House, New York 1999

    Google Scholar 

  4. Sidell FR, Takafuji ET, Franz DR. Medical aspects of chemical and biological warfare. 1997 Textbook of Military Medicine, Office of The Surgeon General, United States Army

    Google Scholar 

  5. Manchee R, Stewart W: The decontamination of Gruinard Island. Chem Br 1988; July:690–691

    Google Scholar 

  6. Manchee RJ, Broster MG, Melling J, Hendstridge RM, Stagg Al. Bacillus anthracis on Gruinard Island. Nature 1981(294):254–255.

    Article  PubMed  CAS  Google Scholar 

  7. Grunow R., Finke E.-J.: Tularämieausbruch im Kosovo-Unterstützung der Labordiagnostik durch das Institut für Mikrobiologie. Wehrmed Mschr 44, Heft 10/2000

    Google Scholar 

  8. Pezard C, Berche P, Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun. 1991;59:3472–3477.

    PubMed  CAS  Google Scholar 

  9. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol. 1957;73:485–494.

    Article  Google Scholar 

  10. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalation al anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA. 1993;90:2291–2294.

    CAS  Google Scholar 

  11. Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management-United States. JAMA 1998;281:787–789.

    Google Scholar 

  12. Young EJ. Human brucellosis. Rev Infect Dis. 1983;5(5):821–842.

    Article  PubMed  CAS  Google Scholar 

  13. Mousa AR, Elhag KM, Khogali M, Marafie AA. The nature of human brucellosis in Kuwait: Study of 379 cases. Rev Infect Dis. 1988;10(1):211–217.

    Article  PubMed  CAS  Google Scholar 

  14. Luzzi GA, Brindle R, Sockett PN, Solera J, Klenerman P, Warrell DA. Brucellosis: Imported and laboratory-acquired cases and an overview of treatment trials. Trans R Soc Trop Med Hyg. 1993;87(2):138–141.

    Article  PubMed  CAS  Google Scholar 

  15. Leelarasamee A, Bovornkitti S: Melioidosis: Review and Update. Rev Infect Dis 1989(11): 413–425

    Google Scholar 

  16. Perry RD, Fetherston JD. Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev 1997(10):35–66.

    PubMed  CAS  Google Scholar 

  17. Centers for Disease Conrol and Prevention. Update: Human Plague-India, 1994. MMWR. 1994;43(41):761–762

    Google Scholar 

  18. Human Plague in 1993. WHO Weekly Epidemiological Record. 17 Feb 1995;7:45–48

    Google Scholar 

  19. Heesemann J, Rakin A. Epidemiologie, Klinik und mikrobiologische Diagnostik der Pest. Antibiotika Monitor XIV. 1998;42–47

    Google Scholar 

  20. Raoult D, Marrie TJ. State-of-the-art clinical lecture: Q fever. Clin Inf Dis. 1995;20:489–496

    Article  CAS  Google Scholar 

  21. Chin J, ed. Control of Communicable Diseases Manual, 17th edition 2000, American Public Health Association, Washington, DC

    Google Scholar 

  22. Everett DE, Templer IW. Oropharyngeal tularemia. Arch Otolaryngol. 1980;106:237–238.

    Article  PubMed  CAS  Google Scholar 

  23. McCrumb FR Jr. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev.1961;25:262–267.

    PubMed  CAS  Google Scholar 

  24. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: A 30-year experience with 88 cases. Medicine. 1985;64:251–269.

    Article  PubMed  CAS  Google Scholar 

  25. Franz D. R. et al.: Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399–411

    Article  PubMed  CAS  Google Scholar 

  26. Fine PEM, Jezek Z, Grab B, Dixon I. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988;17(3):643–650.

    Article  PubMed  CAS  Google Scholar 

  27. First Responder Chem-Bio Handbook. Practical Manual for First Responders. Tempest Publishing; Alexandria, VA 22304-9257 USA

    Google Scholar 

  28. Huggins JW. Prospects tor treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum anti viral drug. Rev Infect Dis. 1989; 11(4);750–761.

    Article  Google Scholar 

  29. Dietz WH, Peralta PH, Johnson KM. Ten clinical cases of human infection with Venezuelan equine encephalomyelitis virus, subtype I-D. Am I Trop Med Hyg. 1979;28:329–334.

    Google Scholar 

  30. Medical management of biological casualties handbook. Fort Detrick, Md: US Army Medical Research Institute of Infectious Diseases; 1998

    Google Scholar 

  31. Centers for Disease Control and Prevention. Management of patients with suspected viral hemorrhagic fever. MMWR. 1988;37(suppl3):1–16

    Google Scholar 

  32. World Health Organization. Health aspects of chemical and biological weapons: Report of a WHO group of consultants. Geneva, Switzerland: WHO 1970

    Google Scholar 

  33. Dove A. Is investment in bioterrorism research warranted? Nature 2001(1):9

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Wien

About this chapter

Cite this chapter

Tomaso, H. (2001). Bioterrorismus — eine reale Bedrohung?. In: Janata, O., Reisinger, E.C. (eds) Infektiologie Aktuelle Aspekte. Infektiologie Aktuelle Aspekte. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6236-1_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6236-1_25

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83662-0

  • Online ISBN: 978-3-7091-6236-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics